Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE)
Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to determine whether regularly scheduled use of an inhaled
long-acting beta agonist (salmeterol) in the setting of concomitant use of inhaled
corticosteroids (beclomethasone hydroflouroalkane (HFA) inhaler) will have a detrimental
effect on asthma control in people who bear the B16-Arg/Arg genotype of the beta-2 adrenergic
receptor gene, as compared to people with asthma of similar severity who bear the B16-Gly/Gly
genotype.
Phase:
Phase 3
Details
Lead Sponsor:
Milton S. Hershey Medical Center
Collaborators:
Asthma Clinical Research Network National Heart, Lung, and Blood Institute (NHLBI)